Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE

[177Lu]Lu-DOTATATE peptide receptor radionuclide therapy is used for treatment of neuroendocrine tumours. We investigated whether prolonging blood residence time of [177Lu]Lu-DOTATATE with albumin binders could increase tumour accumulation and tumour-to-kidney ratios for improved therapeutic efficacy.

Source: Nuclear Medicine and Biology - August 9, 2018 Category: Nuclear Medicine Authors: Etienne Rousseau, Joseph Lau, Zhengxing Zhang, Carlos F. Uribe, Hsiou-Ting Kuo, Chengcheng Zhang, Jutta Zeisler, Nadine Colpo, Kuo-Shyan Lin, Fran çois Bénard Source Type: research